Division of Rheumatology, Department of Medicine.
Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery.
Curr Opin Rheumatol. 2021 Jan;33(1):58-63. doi: 10.1097/BOR.0000000000000767.
A critical unmet need in rheumatoid arthritis (RA) is the identification of biomarkers that predict which of the available medications will be most effective for an individual in order to lower disease activity sooner than is afforded by the current treat-to-target approach. Here we will discuss recent reports examining the potential for synovial tissue molecular, cellular, and spatial profiling in defining objective measures of treatment response and therein developing personalized medicine for RA.
Recent high-dimensional molecular profiling of RA synovium has provided unprecedented resolution of the cell types and pathways in tissues affected by rheumatic diseases. Heightened attention to tissue architecture is also emerging as a means to classify individual disease variation that may allow patients to be further stratified by therapeutic response. Although this wealth of data may have already pinpointed promising biomarkers, additional studies, likely including tissue-based functional drug response assays, will be required to demonstrate how the complex tissue environment responds.
Molecular, cellular, and more recently spatial profiling of the RA synovium are uncovering fundamental features of the disease. Current investigations are examining whether this information will provide meaningful biomarkers for individualized medicine in RA.
类风湿关节炎(RA)的一个关键未满足需求是确定生物标志物,以预测哪些现有药物对个体最有效,从而比目前的达标治疗方法更早地降低疾病活动度。在这里,我们将讨论最近的报告,这些报告探讨了滑膜组织分子、细胞和空间分析在确定治疗反应的客观指标方面的潜力,并在此基础上为 RA 开发个性化药物。
最近对 RA 滑膜的高维分子分析提供了对受风湿性疾病影响的组织中细胞类型和途径的前所未有的分辨率。对组织架构的高度关注也正在成为一种分类个体疾病变异的方法,这可能允许根据治疗反应对患者进行进一步分层。尽管这些大量数据可能已经确定了有前途的生物标志物,但需要进行更多的研究,可能包括基于组织的功能性药物反应测定,以证明复杂的组织环境如何做出反应。
RA 滑膜的分子、细胞,最近还有空间分析正在揭示疾病的基本特征。目前的研究正在探讨这些信息是否将为 RA 的个体化医学提供有意义的生物标志物。